Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) Profit After Tax (2021 - 2025)

Senti Biosciences has reported Profit After Tax over the past 5 years, most recently at -$14.4 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$14.4 million for Q4 2025, down 2340.68% from a year ago — trailing twelve months through Dec 2025 was -$61.4 million (down 16.3% YoY), and the annual figure for FY2025 was -$61.4 million, down 16.31%.
  • Profit After Tax for Q4 2025 was -$14.4 million at Senti Biosciences, up from -$18.1 million in the prior quarter.
  • Over the last five years, Profit After Tax for SNTI hit a ceiling of -$1178.0 in Q1 2021 and a floor of -$83.4 million in Q4 2023.
  • Median Profit After Tax over the past 5 years was -$14.3 million (2025), compared with a mean of -$18.8 million.
  • Biggest five-year swings in Profit After Tax: plummeted 1002276.91% in 2022 and later soared 99.29% in 2024.
  • Senti Biosciences' Profit After Tax stood at -$3.9 million in 2021, then plummeted by 1409.17% to -$58.2 million in 2022, then crashed by 43.28% to -$83.4 million in 2023, then soared by 99.29% to -$590000.0 in 2024, then crashed by 2340.68% to -$14.4 million in 2025.
  • The last three reported values for Profit After Tax were -$14.4 million (Q4 2025), -$18.1 million (Q3 2025), and -$14.7 million (Q2 2025) per Business Quant data.